Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHER: Ultra-hypofractionated vs Hypofractionated Radiation with Chemotherapy for Muscle Invasive Bladder Cancer
NCT07097142Phase 3Recruiting
- Sponsor
- NRG Oncology
- Start
- Oct 2025
- Primary completion
- May 2030
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by NRG Oncology. Primary endpoint: Bladder-Intact Event-Free Survival at 5 years. Started Oct 2025; status: recruiting.
02
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07097142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07097142.